IconICLR
ICLR
About: Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Employees: 41,250
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.56% less ownership
Funds ownership: 92.07% [Q4 2024] → 91.51% (-0.56%) [Q1 2025]
7% less funds holding
Funds holding: 585 [Q4 2024] → 544 (-41) [Q1 2025]
15% less repeat investments, than reductions
Existing positions increased: 186 | Existing positions reduced: 219
18% less capital invested
Capital invested by funds: $15.9B [Q4 2024] → $13.1B (-$2.87B) [Q1 2025]
25% less funds holding in top 10
Funds holding in top 10: 16 [Q4 2024] → 12 (-4) [Q1 2025]
25% less first-time investments, than exits
New positions opened: 71 | Existing positions closed: 95
39% less call options, than puts
Call options by funds: $14.9M | Put options by funds: $24.6M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$150
3%
upside
Avg. target
$172
18%
upside
High target
$215
48%
upside
8 analyst ratings
3 positive
38%
5 neutral
63%
0 negative
0%
Mizuho Ann Hynes | 19%upside $173 | Outperform Maintained | 15 May 2025 |
Barclays Luke Sergott | 6%upside $155 | Equal-Weight Maintained | 2 May 2025 |
Goldman Sachs Matthew Sykes | 10%upside $160 | Neutral Maintained | 2 May 2025 |
Baird Eric Coldwell | 10%upside $160 | Neutral Maintained | 2 May 2025 |
JP Morgan Casey Woodring | 3%upside $150 | Neutral Downgraded | 29 Apr 2025 |
Financial journalist opinion
Based on 9 articles about ICLR published over the past 30 days
Neutral
Business Wire
1 week ago
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm.
Positive
Zacks Investment Research
1 week ago
Here's Why You Should Retain ICLR Stock in Your Portfolio Now
Investors remain optimistic about ICON, driven by its commitment to enhance clinical delivery by integrating AI and impressive strategic pacts.
Neutral
PRNewsWire
1 week ago
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , June 2, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2023 and October 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2025.
Neutral
PRNewsWire
1 week ago
ICLR Shareholders Have the Right to Lead the ICON Public Limited Company Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ICLR
LOS ANGELES , June 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of the federal securities laws. Shareholders who purchased the Company's securities between July 27, 2023 and October 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2025.
Neutral
PRNewsWire
2 weeks ago
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , May 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2023 and October 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2025.
Neutral
Business Wire
2 weeks ago
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the William Blair 45th Annual Growth Stock Conference.
Neutral
PRNewsWire
3 weeks ago
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , May 23, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2023 and October 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2025.
Neutral
Business Wire
3 weeks ago
ICON releases its ICON Cares 2024 Report
DUBLIN--(BUSINESS WIRE)--ICON releases its ICON Cares 2024 Report.
Neutral
PRNewsWire
4 weeks ago
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , May 16, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2023 and October 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2025.
Neutral
Business Wire
1 month ago
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the pote.
Charts implemented using Lightweight Charts™